Presage Biosciences is an oncology company that is pioneering an entirely novel approach to evaluating patient response to drugs in clinical trials.
Using our patented CIVO™ technology, we deliver pharmacologically appropriate concentrations of multiple drugs to different regions of a tumor – while the tumor is still in the patient. Observing molecular and cellular responses to drugs and combinations in an authentic human tumor gives us a far greater understanding of tumor biology, directly embodying a patient’s own immune system, tumor microenvironment, heterogeneity and genetic background. It is Presage’s mission to use this understanding to revolutionize the way drugs are selected, tested and targeted, with the goal of providing more effective treatments to patients with cancer.
Through research alliances, Presage collaborates with biopharmaceutical companies to discover new, effective drug combinations and to identify drug sensitivity and resistance in target patient populations. Presage also is actively developing in-licensed drug candidates and plans to employ CIVO™ to advance a portfolio of promising oncology therapies to the clinic.
March 16, 2015 | Seattle, Wash. Presage Biosciences, an oncology company pioneering a radical new drug development approach that incorporates human efficacy data much earlier in development and clinical trials, announced today the appointment of Brad Margus to its board of directors. Margus is an accomplished entrepreneur and executive who brings broad and deep experience in the biopharmaceutical industry, particularly in building companies with novel science and managing these companies to create significant value.
Presage Biosciences Expands Collaboration with Takeda for CIVO™ Technology to Assess Cancer Drugs Directly in Solid Tumors
November 12, 2014 | Seattle, Wash.
Presage Biosciences, an oncology company developing a radical new testing approach that incorporates human data much earlier in drug development and clinical trials, announced today that it has expanded its cancer research agreement with Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502).